This is a promotional meeting organised and funded by Roche Products Ltd.

Prescribing Information:
Tecentriq®(atezolizumab) 

For the past decade, Roche has brought together the lung cancer community to share expertise, knowledge and solutions to the ever-changing treatment landscape of lung cancer. Last year we launched the Virtual Lung Cancer Expert Forum as a supplementary learning experience to our flagship meeting. In 2020 we are continuing this initiative with a number of virtual meetings, some of which will have a global audience.

We are in challenging times at present and are truly grateful for the difference you are making to the lives of patients during the Covid-19 pandemic. At Roche we feel that providing quality education is still important and therefore would like you to join us for a virtual meeting, in which we will explore various aspects of lung cancer treatment and share expertise from across the community. This webinar will be replicated three times to give everyone the opportunity to attend a time that is convenient to you.

A virtual meeting uses live, online interactive technology to allow delegates to access a meeting remotely. You can join the online presentations and ask text-based questions to be answered in the Q&A session at the end of each meeting.

This is an innovative way to learn about recent developments in treatments of lung cancer and to support best practice learning across the community.

Webinar: Immunotherapy for the management of extensive stage small cell lung cancer

SESSION 1

Wednesday 1st July 2020
18:30 – 19:30 BST

SESSION 2

Monday 6th July
18:30 – 19:30 BST

SESSION 3

Monday 13th July
18:30 – 19:30 BST

Agenda

18:30 – 18:35

Introduction and welcome

 

18:35 – 18:55

Immunotherapy for the management of extensive stage small cell lung cancer:- What does the trial tell us? – Dr Raffaele Califano.

In this session Dr Raffaele Califano, Consultant Medical Oncologist at The Christie Hospital and Manchester University Hospital, will discuss the advances in treatment options for adult patients with ES-SCLC.

 

18:55 – 19:15

Immunotherapy for the management of extensive stage small cell lung cancer :- What does the use in clinical practice give us? – Dr Carles Escriu

In this session Dr Carles Escriu, Consultant Medical Oncologist at Clatterbridge Cancer Centre, discusses his experiences of treating ES-SCLC patients with immunotherapy in combination with chemotherapy.

 

19:15 – 19:30

Live Q&A session

 

19:30

Close

 

Speakers

Dr Raffaele Califano

Consultant Medical Oncologist,
The Christie Hospital and Manchester University Hospital

Dr Carles Escriu

Consultant Medical Oncologist,
Clatterbridge Cancer Centre

Dr Raffaele Califano

Consultant Medical Oncologist at The Christie Hospital and Manchester University Hospital

Dr Raffaele Califano works as Consultant Medical Oncologist at The Christie Hospital and Manchester University Hospital, both in Manchester, United Kingdom. He is also an Honorary Senior Lecturer in Cancer Sciences at The University of Manchester.

Dr Califano has special interest in thoracic malignancies and clinical cancer research and he is an active member of the Manchester Lung Cancer Group.

He graduated in Medicine and Surgery, summa cum laude, from the University of Perugia (Italy) in 2003 and completed his Specialist Training in Medical Oncology in 2007. Dr Califano worked for four years as Clinical Research Fellow with the Lung and Melanoma Team at The Christie Hospital and he has been an investigator for several phase Ib-III clinical trials, developing a particular interest for molecularly-driven clinical trials in advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Mesothelioma.  Dr Califano has a research focus on immunotherapy and oncogenic-driven lung cancer.

Dr Califano serves as Member of the European Society of Medical Oncology (ESMO) Educational Publishing Working Group. He is also a member of British Thoracic Oncology Group (BTOG) and International Association for the Study of Lung Cancer (IASLC).

Dr Califano is the author of several papers published in indexed peer-reviewed international journals and he has been an invited speaker to several national and international oncology meetings.

Dr Carles Escriu

Consultant Medical Oncologist at The Clatterbridge Cancer Centre

Dr Carles Escriu completed medical school in Barcelona. He spent several years working as a junior doctor in several UK hospitals including Leeds General Infirmary and Southampton General Hospital before starting oncology training at Oxford’s Churchill Hospital. Dr Escriu completed a cancer biology PhD at the University of Cambridge before obtaining a higher specialist registration in Liverpool. Now a Consultant Medical oncologist at the Clatterbridge cancer centre, Dr Escriu is currently sub-specialised in thoracic oncology with a specialist interest in targeted treatments and immune therapy.

REGISTER



M-GB-00000083
June 2020

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554. As TECENTRIQ is a biological medicine, healthcare professionals should report adverse reactions by brand name and batch number.

This is a promotional meeting organised and funded by Roche Products Ltd.

The link you have selected will take you away from this site to one that is not owned or controlled by Roche Products Ltd. Roche Products Ltd makes no representation as to the accuracy of the information contained on sites we do not own or control. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.